Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT04061772
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 647
- Registration Number
- NCT04031703
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Breast Cancer Organoids
- Interventions
- Drug: PattozumabDrug: Ear particles
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- Conditions
- Early-stage Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
Combination Therapy of Anthracyclines for Children With Nephroblastoma
- Conditions
- 0.5-14 Year Old Children With Nephroblastoma
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03892330
- Locations
- 🇨🇳
Shenjing Hospital, Shenyang, Liaoning, China
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT03876886
- Locations
- 🇨🇳
National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
- Conditions
- Breast CancerBreast NeoplasmsBreast Diseases
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756090
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03755115
- Locations
- 🇨🇳
Tian Tongde, Zhengzhou, Henan, China
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
- Conditions
- Breast Cancer
- Interventions
- Drug: Placebo (P)Drug: Endocrine therapyRadiation: Radiation therapyProcedure: Surgery
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1240
- Registration Number
- NCT03725059
- Locations
- 🇺🇸
Geisinger Medical Center ( Site 0052), Danville, Pennsylvania, United States
🇦🇺Westmead Hospital ( Site 2101), Sydney, New South Wales, Australia
🇺🇸Massachusetts General Hospital ( Site 0024), Boston, Massachusetts, United States
Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos
- Conditions
- Biliary Tract CancerEsophageal CancerColo-rectal CancerLiver CancerGastric CancerGall Bladder CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- University of Pisa
- Target Recruit Count
- 120
- Registration Number
- NCT03668418
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.